Weight loss and persistence with liraglutide 3.0 mg by obesity class in the real‐world effectiveness study in Canada

OBJECTIVE: Liraglutide 3.0 mg is associated with clinically significant weight loss in clinical trials, but real‐world data are lacking. In this analysis, weight loss and persistence outcomes with liraglutide 3.0 mg were assessed across obesity classes, in a real‐world clinical setting. METHODS: Sec...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Obes Sci Pract
Autores principales: Wharton, Sean, Haase, Christiane L., Kamran, Elham, Liu, Aiden, Mancini, Johanna, Neish, Drew, Pakseresht, Arash, Power, G Sarah, Christensen, Rebecca A. G.
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2020
Materias:
Short Communications
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448201/
https://ncbi.nlm.nih.gov/pubmed/32874678
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/osp4.420
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares